Shares of Speedel Holding AG nearly doubled on Thursday after partner Novartis AG acquired a controlling interest in the biotech and announced plans to buy the remaining shares. (BioWorld Today)
Portola Pharmaceuticals Inc. raised $60 million in a Series C extension round to drive its two lead cardiovascular product candidates through Phase II clinical trials. (BioWorld Today)
When Vanda Pharmaceuticals Inc. released Phase III data showing that insomnia drug tasimelteon (VEC-162) met its primary endpoint of improving short-term sleep onset, the company's stock popped in early trading only to fall more than 15 percent for the day. (BioWorld Financial Watch)
Shares of Vanda Pharmaceuticals Inc. rose and then fell on Thursday as investors tried to digest top-line data from the company's Phase III trial of tasimelteon (VEC-162) in chronic insomnia. (BioWorld Today)
After a year of negotiations, Toronto-based Microbix Biosystems Inc. signed a definitive agreement with the Hunan Provincial Government for the construction of a $200 million flu vaccine manufacturing facility. (BioWorld Today)
